What's new at Łukasiewicz – PORT?

By 2050, one in three people in Europe will be over 60. For care systems, that is a strain; for the economy, it is a market already growing faster than most other sectors. Łukasiewicz – PORT answers both with Senior Living: an open agreement meant to connect scientific research with the real needs of older adults, and whose directions the signatories will define together.

For years, the Photonic Materials Research Group has been developing scintillator technologies, including perovskite materials that could provide a more affordable alternative to conventional crystals. The team is also exploring scintillators that emit in the near-infrared range.

The RESET mobile app supports patients before hospitalization by guiding them through their personalized preoperative plan, sending reminders, and providing direct contact with their care team. It ensures patients receive continuous support throughout their treatment.

As the head of the Translational Neuropsychiatry Research Group at Łukasiewicz – PORT, Dr. Ali Jawaid studies transgenerational trauma and explores how neuroscience can support conflict prevention and mediation.

Glioma has long been a key area of Dr. hab. Grzegorz Chodaczek’s research. His new project, conducted with the 4th Military Clinical Hospital in Wrocław, will center on advancing brain tumor diagnostics.

With nearly PLN 2 million in new funding, Łukasiewicz – PORT will advance work on a photonic biosensor designed to support fast, sensitive diagnostics closer to the patient.

With funding from the Ministry of Science and Higher Education, Dr. Paweł Sega is building the BioValid platform, which will enable the analysis of microorganisms at the single-cell level.

The Biobank Research Group has increased its biological sample collection by 500%, enabling the Population Diagnostics Center, led by Dr. hab. Patrycja Gazińska, to reach a key milestone in the P4Health project funded under Teaming for Excellence.

The Virtual Research Institute (WIB), operating within the structure of Łukasiewicz – PORT, is seeking partners for the commercialization of an innovative mRNA-based technology. The technology was developed by one of WIB’s research teams, and we are looking for a partner to help further develop and bring it to market.

Precision medicine is transforming diagnosis and treatment, requiring advanced molecular analysis, deep insight into disease mechanisms, and high-quality biological samples, making close collaboration between researchers, laboratories, and hospitals essential for implementing innovative therapies.